About Xilio Therapeutics, Inc. (XLO): stock profile, AI score and financials
Xilio Therapeutics, Inc. (XLO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XLO at 35.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,282 of 2,925 stocks — the bottom half of the AI-ranked universe. XLO scores in the top quartile across institutional flow (98.8), revenue growth (98.4). Areas of concern include earnings quality (1.0) and free cash flow (6.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xilio Therapeutics, Inc. reports quarterly revenue of $18.7M, net income of $-6.4M, an operating margin of -18.7%. Top institutional holders of XLO by reported 13-F value include Bain Capital Life Sciences Investors, GILEAD SCIENCES, ORBIMED ADVISORS, based on the most recent SEC filings. XLO trades on the Nasdaq exchange and files with the SEC under CIK 1840233. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XLO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xilio Therapeutics, Inc. directly from SEC EDGAR.